ERBB2 T798I

CI-VAR-00004343Explore in graph →NP_001276866.1:p.Thr798IleNM_001289937.1:c.2393C>TCIViC 2331

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm3
ERBB2 T798I	Afatinib	Predictive	D	Does Not Support Resistance	2	submitted	EID6176 Efficacy of afatinib at reducing phosphorylation of key proteins was evaluated by western blot. NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I responded to afatinib treatmen… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC	civic
ERBB2 T798I	Neratinib	Predictive	C	Supports Resistance	3	submitted	EID6175 A 54-year-old female with estrogen and progesterone receptor positive, ERBB2 non-amplified lobular heavily pretreated metastatic breast carcinoma harboring ERBB2 L869R, a CDH1 truncating mutation, ERB… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.